1. Home
  2. TDTH vs RNTX Comparison

TDTH vs RNTX Comparison

Compare TDTH & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TDTH
  • RNTX
  • Stock Information
  • Founded
  • TDTH 2014
  • RNTX 2001
  • Country
  • TDTH Singapore
  • RNTX United States
  • Employees
  • TDTH N/A
  • RNTX N/A
  • Industry
  • TDTH
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TDTH
  • RNTX Health Care
  • Exchange
  • TDTH NYSE
  • RNTX Nasdaq
  • Market Cap
  • TDTH 42.7M
  • RNTX 44.2M
  • IPO Year
  • TDTH 2024
  • RNTX N/A
  • Fundamental
  • Price
  • TDTH $0.23
  • RNTX $1.70
  • Analyst Decision
  • TDTH
  • RNTX
  • Analyst Count
  • TDTH 0
  • RNTX 0
  • Target Price
  • TDTH N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • TDTH 3.9M
  • RNTX 26.3K
  • Earning Date
  • TDTH 05-25-2025
  • RNTX 04-07-2025
  • Dividend Yield
  • TDTH N/A
  • RNTX N/A
  • EPS Growth
  • TDTH N/A
  • RNTX N/A
  • EPS
  • TDTH N/A
  • RNTX N/A
  • Revenue
  • TDTH $1,380,783.00
  • RNTX N/A
  • Revenue This Year
  • TDTH N/A
  • RNTX N/A
  • Revenue Next Year
  • TDTH N/A
  • RNTX N/A
  • P/E Ratio
  • TDTH N/A
  • RNTX N/A
  • Revenue Growth
  • TDTH 8.81
  • RNTX N/A
  • 52 Week Low
  • TDTH $0.20
  • RNTX $1.35
  • 52 Week High
  • TDTH $4.74
  • RNTX $7.42
  • Technical
  • Relative Strength Index (RSI)
  • TDTH N/A
  • RNTX N/A
  • Support Level
  • TDTH N/A
  • RNTX N/A
  • Resistance Level
  • TDTH N/A
  • RNTX N/A
  • Average True Range (ATR)
  • TDTH 0.00
  • RNTX 0.00
  • MACD
  • TDTH 0.00
  • RNTX 0.00
  • Stochastic Oscillator
  • TDTH 0.00
  • RNTX 0.00

About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B

Trident Digital Tech Holdings is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.

Share on Social Networks: